Profile of ramucirumab in the treatment of metastatic non-small-cell lung cancer.
The interaction between vascular endothelial growth factor and its receptor is an important therapeutic target due to the importance of this pathway in carcinogenesis. In particular, this pathway promotes and regulates angiogenesis as well as increases endothelial cell proliferation, permeability, and survival. Ramucirumab is a fully human monoclonal antibody that specifically targets the vascular endothelial growth factor receptor-2, the key receptor implicated in angiogenesis. Currently, ramucirumab is approved for the second-line treatment of metastatic non-small-cell lung cancer (NSCLC) in combination with docetaxel. In a Phase III clinical trial, ramucirumab was shown to improve the overall survival in patients with disease progression, despite platinum-based chemotherapy for advanced NSCLC. This review describes the pharmacology, pharmacokinetics and dynamics, adverse event profile, and the clinical activity of ramucirumab observed in Phase II and III trials in NSCLC.
Department of Pharmacy Practice, School of Pharmacy - Worcester/Manchester, MCPHS University, Manchester, NH, USA.
Maryann R
MR
Cooper
School of Pharmacy - Boston, MCPHS University, Boston, MA, USA; North America Medical Affairs, Sanofi Oncology, Cambridge, MA, USA.
Chelsea
C
Binkowski
School of Pharmacy - Boston, MCPHS University, Boston, MA, USA; Global Medical Affairs, Sanofi Oncology, Cambridge, MA, USA.
Jessica
J
Hartung
Department of Pharmacy Practice, School of Pharmacy - Worcester/Manchester, MCPHS University, Manchester, NH, USA.
Jennifer
J
Towle
NSCLC; VEGF-targeted therapy; antiangiogenesis